Banque Pictet & Cie’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Banque Pictet & Cie’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,571	Closed	-$2.34M	–	641
2022 Q4	$2.34M	Sell	20,571 -6,489	-24%	-$539K	0.02%	261
2022 Q3	$1.67M	Buy	27,060 +4,005	+17%	+$280K	0.02%	316
2022 Q2	$1.84K	Sell	23,055 -2,219	-9%	-$210K	0.02%	316
2022 Q1	$2.66M	Buy	25,274 +978	+4%	+$95.3K	0.02%	277
2021 Q4	$2.62M	Buy	+24,296	New	+$2.65M	0.02%	290

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Banque Pictet & Cie's HZNP Position: Q1 2023 in Review

Banque Pictet & Cie sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 20,571 shares — an estimated $2.34M sold.

Banque Pictet & Cie first reported a position in HZNP in Q4 2021 and held it in 5 quarters. The position peaked at $2.66M in Q1 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Banque Pictet & Cie reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Banque Pictet & Cie sold 20,571 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $2.34M.
Banque Pictet & Cie first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and held it in 5 quarters.
Banque Pictet & Cie's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.66M in Q1 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Banque Pictet & Cie's 13F filing for Q1 2023, filed 1 May 2023.